This is a published notice on the Find a Tender service: <u>https://www.find-tender.service.gov.uk/Notice/036469-2024</u>

# Not applicable Centralised Adult Flu Procurement

Secretary of State for Health and Social Care acting as part of the Crown through UK Health Security Agency

F14: Notice for changes or additional information Notice identifier: 2024/S 000-036469 Procurement identifier (OCID): ocds-h6vhtk-04b1c0 Published 11 November 2024, 4:03pm

# Section I: Contracting authority/entity

## I.1) Name and addresses

Secretary of State for Health and Social Care acting as part of the Crown through UK Health Security Agency

10 South Colonnade

London

E14 4PU

### Contact

Major Programmes, UKHSA

Email

majorprogrammespin@ukhsa.gov.uk

Country

United Kingdom

### **Region code**

UKI42 - Tower Hamlets

### Internet address(es)

Main address

https://www.gov.uk/government/organisations/uk-health-security-agency

Buyer's address

https://www.gov.uk/government/organisations/uk-health-security-agency

# **Section II: Object**

## II.1) Scope of the procurement

## II.1.1) Title

Centralised Adult Flu Procurement

### II.1.2) Main CPV code

• 33651600 - Vaccines

### II.1.3) Type of contract

Supplies

### II.1.4) Short description

Following the publication of the NHS Vaccination Strategy (2023), NHSE, UKHSA and DHSC are exploring whether centralising the procurement and/or supply of adult flu vaccine could deliver a more efficient and effective outcome and provide improvements on the current models.

# Section VI. Complementary information

## VI.6) Original notice reference

Notice number: 2024/S 000-034816

## Section VII. Changes

### VII.1.2) Text to be corrected in the original notice

Section number

II.2.4.1

Instead of

Text

UKHSA, as the potential Contracting Authority, are leading the pre-market engagement activity with the purpose to: Gain a better understanding of the 'as-is' adult NHS flu programme from the perspective of vaccine manufacturers and wholesalers • Understand what impact centralising the procurement and/or supply of adult flu vaccine would potentially have on the market including current capability and capacity; options under consideration includeo Procuring Adult Flu Vaccines using a Centralised Framework Contracto UKHSA Procuring Adult Flu Vaccines and maintaining existing supply and distribution methodso UKHSA Procuring Adult Flu Vaccines and ingesting supply centrally for distribution o Maintaining the status quo. Explore any potential barriers, opportunities, benefits or risks there may be with a central procurement and/or supply approach. Have an open dialogue with the market to ensure a full understanding of the future landscape. The market engagement will take the form of a questionnaire available via our e-procurement system, which you will be asked to complete and return. Once returned, you may be invited for a 1:1 meeting with the project team to discuss your answers and provide clarification. It is anticipated that these meetings will take place during November/December 2024. Who would we like to hear from? We are keen to engage with those suppliers who already have a licenced adult flu vaccine and/or have experience of the UK adult flu market, who have an adult flu vaccine in development, or who may have an adult flu vaccine in their future product development pipeline, and with medical logistics providers both wholesale and distribution. How to participate? The opportunity will be available on the Atamis eTendering system, access here: https://atamis-1928.my.site.com/s/Welcome. If you do not already have an account you can easily register for one via the same link. You will then be able to search for this opportunity and access the questionnaire and any other related documents. Please note that all correspondence must be conducted through the Atamis system. The

response window will close at 5pm on Sunday 17th November 2024.

Read

Text

UKHSA, as the potential Contracting Authority, are leading the pre-market engagement activity with the purpose to: Gain a better understanding of the 'as-is' adult NHS flu programme from the perspective of vaccine manufacturers and wholesalers • Understand what impact centralising the procurement and/or supply of adult flu vaccine would potentially have on the market including current capability and capacity; options under consideration includeo Procuring Adult Flu Vaccines using a Centralised Framework Contracto UKHSA Procuring Adult Flu Vaccines and maintaining existing supply and distribution methodso UKHSA Procuring Adult Flu Vaccines and ingesting supply centrally for distribution o Maintaining the status quo• Explore any potential barriers, opportunities, benefits or risks there may be with a central procurement and/or supply approach. Have an open dialogue with the market to ensure a full understanding of the future landscape. The market engagement will take the form of a questionnaire available via our e-procurement system, which you will be asked to complete and return. Once returned, you may be invited for a 1:1 meeting with the project team to discuss your answers and provide clarification. It is anticipated that these meetings will take place during November/December 2024. Who would we like to hear from?We are keen to engage with those suppliers who already have a licenced adult flu vaccine and/or have experience of the UK adult flu market, who have an adult flu vaccine in development, or who may have an adult flu vaccine in their future product development pipeline, and with medical logistics providers both wholesale and distribution. How to participate? The opportunity will be available on the Atamis eTendering system, access here: https://atamis-1928.my.site.com/s/Welcome. If you do not already have an account you can easily register for one via the same link. You will then be able to search for this opportunity and access the questionnaire and any other related documents. Please note that all correspondence must be conducted through the Atamis system. The response window will close at 5pm on Friday 29th November 2024.